Share Price and Basic Stock Data
Last Updated: January 9, 2026, 2:54 am
| PEG Ratio | -3.93 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Glaxosmithkline Pharmaceuticals Ltd, operating in the pharmaceuticals sector, reported a current market price of ₹2,460 and a market capitalization of ₹41,688 Cr. The company’s revenue has shown resilience with sales standing at ₹3,252 Cr for the fiscal year ending March 2023, a notable decrease from ₹3,278 Cr in March 2022. However, the trailing twelve months (TTM) revenue improved to ₹3,709 Cr, indicating a recovery trend. Quarterly sales have also fluctuated, with a recent high of ₹957 Cr in September 2023, following a low of ₹762 Cr in June 2023. This variance reflects the company’s ability to adapt to market conditions, although it also denotes potential volatility. The operating profit margin (OPM) has averaged around 25% over the last year, with a peak of 34% reported in September 2025. Overall, the company’s revenue trajectory indicates a cautiously optimistic outlook, bolstered by recent sales momentum.
Profitability and Efficiency Metrics
Glaxosmithkline Pharmaceuticals Ltd has demonstrated strong profitability metrics, with a reported net profit of ₹955 Cr for the most recent fiscal year, translating to an impressive return on equity (ROE) of 46.9%. The company’s operating profit for the year stood at ₹804 Cr, with an OPM of 25%, which highlights effective cost management despite fluctuating sales. The interest coverage ratio (ICR) reported at 1007.30x signifies exceptional ability to meet interest obligations, reflecting low financial risk. The cash conversion cycle (CCC) is notably negative at -31 days, indicating efficient management of receivables and payables. However, the company faces challenges with its net profit margin, which has varied significantly, recording a high of 51.69% in March 2022 and dropping to 24.74% in March 2025. These metrics underline both the strength and volatility in profitability, suggesting a need for ongoing strategic management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Glaxosmithkline Pharmaceuticals Ltd reveals a robust financial position, with total assets reported at ₹4,108 Cr and minimal borrowings of ₹36 Cr, underscoring a conservative capital structure. The company’s reserves stood at ₹1,538 Cr, providing a solid buffer against operational uncertainties. The price-to-book value (P/BV) ratio is relatively high at 24.98x, indicating that the market values the company at a premium compared to its book value, which may reflect investor confidence in future growth. Financial ratios such as the current ratio of 1.79 and quick ratio of 1.54 suggest sufficient liquidity to meet short-term obligations. However, the high P/BV ratio could also indicate overvaluation concerns. Additionally, the return on capital employed (ROCE) of 63.2% demonstrates efficient use of capital, positioning the company favorably within the sector.
Shareholding Pattern and Investor Confidence
Glaxosmithkline Pharmaceuticals Ltd maintains a stable shareholding structure, with promoters holding 75% of the equity, which reflects strong insider confidence in the company’s future. Foreign institutional investors (FIIs) have increased their stake to 4.79%, while domestic institutional investors (DIIs) hold 7.75%, indicating a balanced interest from both domestic and international investors. The public shareholding is recorded at 12.45%, with the number of shareholders rising to 1,22,904 as of September 2025, suggesting a growing retail investor base. However, the recent decline in DII holdings from 10.29% in December 2022 to 7.75% in September 2025 may raise concerns regarding institutional sentiment. The overall distribution points to a robust confidence level among promoters and a cautious yet present interest from institutional investors, which is vital for long-term stability.
Outlook, Risks, and Final Insight
Looking ahead, Glaxosmithkline Pharmaceuticals Ltd faces both opportunities and challenges. The continued improvement in quarterly sales and profitability metrics suggests a potential for sustained growth, particularly if operational efficiencies are maintained. However, the volatility in profit margins and fluctuating institutional holdings may pose risks to investor confidence. Potential regulatory changes and competitive pressures within the pharmaceutical sector could also impact future performance. Strengths include a solid balance sheet with minimal debt and strong profitability ratios, while risks encompass market volatility and fluctuating demand for pharmaceutical products. In conclusion, the company’s strategic positioning and operational efficiency are critical as it navigates these challenges, with the potential for significant upside if it can stabilize its profit margins and maintain investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,407 Cr. | 404 | 479/192 | 91.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,548.27 Cr | 1,144.26 | 53.57 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of Glaxosmithkline Pharmaceuticals Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 917 | 802 | 787 | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 |
| Expenses | 660 | 574 | 618 | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 |
| Operating Profit | 257 | 229 | 170 | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 |
| OPM % | 28% | 29% | 22% | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% |
| Other Income | 22 | 12 | 38 | 54 | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Depreciation | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 |
| Profit before tax | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 |
| Tax % | 26% | 27% | 30% | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% |
| Net Profit | 193 | 165 | 133 | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 |
| EPS in Rs | 11.42 | 9.71 | 7.88 | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 |
Last Updated: January 1, 2026, 4:16 pm
Below is a detailed analysis of the quarterly data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 980.00 Cr.. The value appears strong and on an upward trend. It has increased from 805.00 Cr. (Jun 2025) to 980.00 Cr., marking an increase of 175.00 Cr..
- For Expenses, as of Sep 2025, the value is 644.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 554.00 Cr. (Jun 2025) to 644.00 Cr., marking an increase of 90.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 336.00 Cr.. The value appears strong and on an upward trend. It has increased from 251.00 Cr. (Jun 2025) to 336.00 Cr., marking an increase of 85.00 Cr..
- For OPM %, as of Sep 2025, the value is 34.00%. The value appears strong and on an upward trend. It has increased from 31.00% (Jun 2025) to 34.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 44.00 Cr. (Jun 2025) to 36.00 Cr., marking a decrease of 8.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Jun 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 17.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Jun 2025) to 17.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 354.00 Cr.. The value appears strong and on an upward trend. It has increased from 279.00 Cr. (Jun 2025) to 354.00 Cr., marking an increase of 75.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 27.00%.
- For Net Profit, as of Sep 2025, the value is 257.00 Cr.. The value appears strong and on an upward trend. It has increased from 205.00 Cr. (Jun 2025) to 257.00 Cr., marking an increase of 52.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 15.20. The value appears strong and on an upward trend. It has increased from 12.10 (Jun 2025) to 15.20, marking an increase of 3.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:20 am
| Metric | Dec 2013 | Mar 2015n n 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,563 | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,709 |
| Expenses | 2,034 | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,497 |
| Operating Profit | 528 | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,212 |
| OPM % | 21% | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 31% | 33% |
| Other Income | 203 | 149 | 125 | 119 | 70 | 131 | -262 | 9 | 1,401 | 103 | -21 | 149 | 156 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 20 | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 66 |
| Profit before tax | 711 | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 816 | 1,260 | 1,300 |
| Tax % | 32% | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | 28% | 26% | |
| Net Profit | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 955 |
| EPS in Rs | 28.43 | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 56.39 |
| Dividend Payout % | 88% | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% | 92% | 99% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -10.37% | 4.15% | 26.78% | -79.10% | 284.95% | 373.46% | -63.95% | -3.44% | 57.29% |
| Change in YoY Net Profit Growth (%) | 0.00% | 14.53% | 22.63% | -105.88% | 364.05% | 88.52% | -437.42% | 60.52% | 60.73% |
Glaxosmithkline Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 3% |
| 3 Years: | 5% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 35% |
| 3 Years: | -20% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 13% |
| 3 Years: | 26% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 45% |
| 3 Years: | 36% |
| Last Year: | 47% |
Last Updated: September 5, 2025, 4:50 am
Balance Sheet
Last Updated: January 7, 2026, 3:43 pm
| Month | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1,905 | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 1,538 |
| Borrowings | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 36 |
| Other Liabilities | 1,136 | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,315 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 1,922 |
| Total Liabilities | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 3,665 |
| Fixed Assets | 100 | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 291 |
| CWIP | 62 | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 17 |
| Investments | 10 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,313 |
| Other Assets | 2,958 | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,044 |
| Total Assets | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 3,665 |
Below is a detailed analysis of the balance sheet data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 169.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,538.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,782.00 Cr. (Mar 2025) to 1,538.00 Cr., marking a decrease of 244.00 Cr..
- For Borrowings, as of Sep 2025, the value is 36.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 10.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 26.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,922.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,147.00 Cr. (Mar 2025) to 1,922.00 Cr., marking a decrease of 225.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,665.00 Cr.. The value appears to be improving (decreasing). It has decreased from 4,108.00 Cr. (Mar 2025) to 3,665.00 Cr., marking a decrease of 443.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 291.00 Cr.. The value appears strong and on an upward trend. It has increased from 284.00 Cr. (Mar 2025) to 291.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 3.00 Cr..
- For Investments, as of Sep 2025, the value is 1,313.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,118.00 Cr. (Mar 2025) to 1,313.00 Cr., marking an increase of 195.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,044.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,692.00 Cr. (Mar 2025) to 2,044.00 Cr., marking a decrease of 648.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,665.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,108.00 Cr. (Mar 2025) to 3,665.00 Cr., marking a decrease of 443.00 Cr..
Notably, the Reserves (1,538.00 Cr.) exceed the Borrowings (36.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2013 | Mar 2015n n 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 524.00 | 633.00 | 476.00 | 418.00 | 507.00 | 600.00 | 657.00 | 563.00 | 742.00 | 788.00 | 890.00 | -9.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 14 | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 | 28 |
| Inventory Days | 109 | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 | 126 |
| Days Payable | 90 | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 | 186 |
| Cash Conversion Cycle | 33 | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 | -4 | -31 |
| Working Capital Days | -45 | -48 | 26 | 7 | -90 | -72 | -38 | -39 | -94 | -57 | -64 | -99 |
| ROCE % | 34% | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% | 63% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Midcap Fund | 1,200,000 | 1.32 | 308.34 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 1,100,000 | 0.94 | 282.65 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 913,226 | 2.77 | 234.65 | 853,907 | 2025-12-08 01:23:05 | 6.95% |
| Nippon India Growth Mid Cap Fund | 559,000 | 0.34 | 143.64 | N/A | N/A | N/A |
| Kotak Flexicap Fund | 399,331 | 0.18 | 102.61 | N/A | N/A | N/A |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 333,621 | 0.55 | 85.72 | 532,312 | 2025-12-15 01:10:59 | -37.33% |
| Aditya Birla Sun Life MNC Fund | 260,835 | 1.85 | 67.02 | N/A | N/A | N/A |
| Bandhan ELSS Tax Saver Fund | 230,000 | 0.81 | 59.1 | 220,000 | 2025-12-15 01:10:59 | 4.55% |
| Aditya Birla Sun Life Multi-Cap Fund | 227,787 | 0.86 | 58.53 | N/A | N/A | N/A |
| Mahindra Manulife Small Cap Fund | 182,918 | 1.11 | 47 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 54.52 | 41.14 | 36.08 | 99.29 | 31.35 |
| Diluted EPS (Rs.) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 |
| Cash EPS (Rs.) | 58.70 | 38.94 | 39.93 | 104.06 | 25.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 115.19 | 104.93 | 102.79 | 157.19 | 87.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 115.19 | 104.93 | 102.79 | 157.19 | 87.26 |
| Revenue From Operations / Share (Rs.) | 221.32 | 203.87 | 191.95 | 193.50 | 172.70 |
| PBDIT / Share (Rs.) | 78.11 | 60.88 | 53.42 | 49.45 | 41.84 |
| PBIT / Share (Rs.) | 74.17 | 56.76 | 49.54 | 45.42 | 37.20 |
| PBT / Share (Rs.) | 74.37 | 48.18 | 49.37 | 45.99 | 26.80 |
| Net Profit / Share (Rs.) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 |
| NP After MI And SOA / Share (Rs.) | 54.91 | 35.07 | 36.41 | 100.04 | 21.14 |
| PBDIT Margin (%) | 35.29 | 29.86 | 27.82 | 25.55 | 24.22 |
| PBIT Margin (%) | 33.51 | 27.84 | 25.80 | 23.47 | 21.53 |
| PBT Margin (%) | 33.60 | 23.63 | 25.72 | 23.76 | 15.51 |
| Net Profit Margin (%) | 24.74 | 17.08 | 18.78 | 51.69 | 12.24 |
| NP After MI And SOA Margin (%) | 24.81 | 17.20 | 18.96 | 51.69 | 12.24 |
| Return on Networth / Equity (%) | 47.67 | 33.42 | 35.41 | 63.64 | 24.22 |
| Return on Capital Employeed (%) | 57.03 | 47.33 | 41.95 | 26.21 | 35.80 |
| Return On Assets (%) | 22.64 | 16.70 | 18.53 | 36.57 | 11.49 |
| Asset Turnover Ratio (%) | 0.97 | 1.00 | 0.80 | 0.83 | 0.93 |
| Current Ratio (X) | 1.79 | 1.84 | 1.88 | 2.18 | 1.63 |
| Quick Ratio (X) | 1.54 | 1.49 | 1.53 | 1.87 | 1.22 |
| Inventory Turnover Ratio (X) | 7.45 | 1.11 | 0.81 | 1.04 | 0.89 |
| Dividend Payout Ratio (NP) (%) | 80.12 | 91.24 | 247.21 | 29.98 | 189.20 |
| Dividend Payout Ratio (CP) (%) | 74.76 | 81.66 | 223.39 | 28.82 | 155.15 |
| Earning Retention Ratio (%) | 19.88 | 8.76 | -147.21 | 70.02 | -89.20 |
| Cash Earning Retention Ratio (%) | 25.24 | 18.34 | -123.39 | 71.18 | -55.15 |
| Interest Coverage Ratio (X) | 1007.30 | 573.35 | 499.36 | 419.65 | 200.69 |
| Interest Coverage Ratio (Post Tax) (X) | 703.51 | 408.84 | 336.84 | 185.96 | 131.22 |
| Enterprise Value (Cr.) | 47339.67 | 31854.06 | 21275.97 | 25686.86 | 23243.30 |
| EV / Net Operating Revenue (X) | 12.63 | 9.22 | 6.54 | 7.84 | 7.94 |
| EV / EBITDA (X) | 35.77 | 30.89 | 23.51 | 30.67 | 32.80 |
| MarketCap / Net Operating Revenue (X) | 13.00 | 9.53 | 6.90 | 8.59 | 8.34 |
| Retention Ratios (%) | 19.87 | 8.75 | -147.21 | 70.01 | -89.20 |
| Price / BV (X) | 24.98 | 18.52 | 12.88 | 10.58 | 16.51 |
| Price / Net Operating Revenue (X) | 13.00 | 9.53 | 6.90 | 8.59 | 8.34 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.06 | 0.01 |
After reviewing the key financial ratios for Glaxosmithkline Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 54.52. This value is within the healthy range. It has increased from 41.14 (Mar 24) to 54.52, marking an increase of 13.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 54.76. This value is within the healthy range. It has increased from 34.83 (Mar 24) to 54.76, marking an increase of 19.93.
- For Cash EPS (Rs.), as of Mar 25, the value is 58.70. This value is within the healthy range. It has increased from 38.94 (Mar 24) to 58.70, marking an increase of 19.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 115.19. It has increased from 104.93 (Mar 24) to 115.19, marking an increase of 10.26.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 115.19. It has increased from 104.93 (Mar 24) to 115.19, marking an increase of 10.26.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 221.32. It has increased from 203.87 (Mar 24) to 221.32, marking an increase of 17.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 78.11. This value is within the healthy range. It has increased from 60.88 (Mar 24) to 78.11, marking an increase of 17.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 74.17. This value is within the healthy range. It has increased from 56.76 (Mar 24) to 74.17, marking an increase of 17.41.
- For PBT / Share (Rs.), as of Mar 25, the value is 74.37. This value is within the healthy range. It has increased from 48.18 (Mar 24) to 74.37, marking an increase of 26.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 54.76. This value is within the healthy range. It has increased from 34.83 (Mar 24) to 54.76, marking an increase of 19.93.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 54.91. This value is within the healthy range. It has increased from 35.07 (Mar 24) to 54.91, marking an increase of 19.84.
- For PBDIT Margin (%), as of Mar 25, the value is 35.29. This value is within the healthy range. It has increased from 29.86 (Mar 24) to 35.29, marking an increase of 5.43.
- For PBIT Margin (%), as of Mar 25, the value is 33.51. This value exceeds the healthy maximum of 20. It has increased from 27.84 (Mar 24) to 33.51, marking an increase of 5.67.
- For PBT Margin (%), as of Mar 25, the value is 33.60. This value is within the healthy range. It has increased from 23.63 (Mar 24) to 33.60, marking an increase of 9.97.
- For Net Profit Margin (%), as of Mar 25, the value is 24.74. This value exceeds the healthy maximum of 10. It has increased from 17.08 (Mar 24) to 24.74, marking an increase of 7.66.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 24.81. This value exceeds the healthy maximum of 20. It has increased from 17.20 (Mar 24) to 24.81, marking an increase of 7.61.
- For Return on Networth / Equity (%), as of Mar 25, the value is 47.67. This value is within the healthy range. It has increased from 33.42 (Mar 24) to 47.67, marking an increase of 14.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 57.03. This value is within the healthy range. It has increased from 47.33 (Mar 24) to 57.03, marking an increase of 9.70.
- For Return On Assets (%), as of Mar 25, the value is 22.64. This value is within the healthy range. It has increased from 16.70 (Mar 24) to 22.64, marking an increase of 5.94.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.97. It has decreased from 1.00 (Mar 24) to 0.97, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has decreased from 1.84 (Mar 24) to 1.79, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has increased from 1.49 (Mar 24) to 1.54, marking an increase of 0.05.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.45. This value is within the healthy range. It has increased from 1.11 (Mar 24) to 7.45, marking an increase of 6.34.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 80.12. This value exceeds the healthy maximum of 50. It has decreased from 91.24 (Mar 24) to 80.12, marking a decrease of 11.12.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 74.76. This value exceeds the healthy maximum of 50. It has decreased from 81.66 (Mar 24) to 74.76, marking a decrease of 6.90.
- For Earning Retention Ratio (%), as of Mar 25, the value is 19.88. This value is below the healthy minimum of 40. It has increased from 8.76 (Mar 24) to 19.88, marking an increase of 11.12.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 25.24. This value is below the healthy minimum of 40. It has increased from 18.34 (Mar 24) to 25.24, marking an increase of 6.90.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,007.30. This value is within the healthy range. It has increased from 573.35 (Mar 24) to 1,007.30, marking an increase of 433.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 703.51. This value is within the healthy range. It has increased from 408.84 (Mar 24) to 703.51, marking an increase of 294.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 47,339.67. It has increased from 31,854.06 (Mar 24) to 47,339.67, marking an increase of 15,485.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.63. This value exceeds the healthy maximum of 3. It has increased from 9.22 (Mar 24) to 12.63, marking an increase of 3.41.
- For EV / EBITDA (X), as of Mar 25, the value is 35.77. This value exceeds the healthy maximum of 15. It has increased from 30.89 (Mar 24) to 35.77, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 3. It has increased from 9.53 (Mar 24) to 13.00, marking an increase of 3.47.
- For Retention Ratios (%), as of Mar 25, the value is 19.87. This value is below the healthy minimum of 30. It has increased from 8.75 (Mar 24) to 19.87, marking an increase of 11.12.
- For Price / BV (X), as of Mar 25, the value is 24.98. This value exceeds the healthy maximum of 3. It has increased from 18.52 (Mar 24) to 24.98, marking an increase of 6.46.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 3. It has increased from 9.53 (Mar 24) to 13.00, marking an increase of 3.47.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glaxosmithkline Pharmaceuticals Ltd:
- Net Profit Margin: 24.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 57.03% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 47.67% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 703.51
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.54
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 42.6 (Industry average Stock P/E: 53.57)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 24.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | GSK House, Dr. Annie Besant Road, Mumbai Maharashtra 400030 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Ms. R S Karnad | Chairperson |
| Mr. B Akshikar | Managing Director |
| Mr. J Chandy | WholeTime Director & CFO |
| Mr. S Williams | Non Executive Director |
| Mr. M Anand | Independent Director |
| Mr. P R Somasundaram | Independent Director |
| Dr. A Wadhawan | Independent Director |
| Dr.(Ms.) S Maheshwari | Independent Director |
FAQ
What is the intrinsic value of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's intrinsic value (as of 09 January 2026) is ₹1642.59 which is 31.53% lower the current market price of ₹2,399.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹40,635 Cr. market cap, FY2025-2026 high/low of ₹3,516/1,921, reserves of ₹1,538 Cr, and liabilities of ₹3,665 Cr.
What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?
The Market Cap of Glaxosmithkline Pharmaceuticals Ltd is 40,635 Cr..
What is the current Stock Price of Glaxosmithkline Pharmaceuticals Ltd as on 09 January 2026?
The current stock price of Glaxosmithkline Pharmaceuticals Ltd as on 09 January 2026 is ₹2,399.
What is the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks is ₹3,516/1,921.
What is the Stock P/E of Glaxosmithkline Pharmaceuticals Ltd?
The Stock P/E of Glaxosmithkline Pharmaceuticals Ltd is 42.6.
What is the Book Value of Glaxosmithkline Pharmaceuticals Ltd?
The Book Value of Glaxosmithkline Pharmaceuticals Ltd is 101.
What is the Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd?
The Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd is 1.75 %.
What is the ROCE of Glaxosmithkline Pharmaceuticals Ltd?
The ROCE of Glaxosmithkline Pharmaceuticals Ltd is 63.2 %.
What is the ROE of Glaxosmithkline Pharmaceuticals Ltd?
The ROE of Glaxosmithkline Pharmaceuticals Ltd is 46.9 %.
What is the Face Value of Glaxosmithkline Pharmaceuticals Ltd?
The Face Value of Glaxosmithkline Pharmaceuticals Ltd is 10.0.